Portland's strategy on track
Wednesday, 25 June, 2008
Portland Orthopedics' (ASX: PLD) strategy of expanding the distribution of its hip replacement products in the US and Australian markets seems to be working, investors were told yesterday, but the company is yet to see profitability.
By the end of June Portland's artifical hips will have been implanted in 480 US patients and 100 Australian patients within the last 12 months, according to company predictions.
Portland has also lodged a non-renounceable rights issue, offering existing shareholders a one-for-one deal to raise up to $4 million.
The company said it had made major reductions in its operating costs, and is seeing a double-figure revenue increase in 2008 compared to the first half of the financial year.
Portland's next immediate goal is to achieve profitability and positive cash flow.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
